domingo, 9 de enero de 2022

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab - The Lancet Rheumatology

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab - The Lancet Rheumatology

No hay comentarios:

Publicar un comentario